Results 21 to 30 of about 379,801 (144)

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

Vaccines, 2022
Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens.
Ulrika Marking, Sebastian Havervall, Nina Greilert-Norin, Henry Ng, Kim Blom, Peter Nilsson, Mia Phillipson, Sophia Hober, Charlotta Nilsson, Sara Mangsbo, Wanda Christ, Jonas Klingström, Max Gordon, Mikael Åberg, Charlotte Thålin   +14 more
doaj   +1 more source

Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea [PDF]

Epidemiology and Health, 2022
OBJECTIVES In Korea, a national coronavirus disease 2019 (COVID-19) vaccination program was implemented, including 4 vaccines against COVID-19. A text messaging-based survey, in addition to a passive adverse event reporting system, was launched to ...
Yunhyung Kwon, Insob Hwang, Mijeong Ko, Hyungjun Kim, Seontae Kim, Soon-Young Seo, Enhi Cho, Yeon-Kyeng Lee   +7 more
doaj   +1 more source

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination [PDF]

, 2021
Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available.
Guckelmus, Candida, Schneitler, Sophie, Klemis, Verena, Schub, David, Hielscher, Franziska, Marx, Stefanie, Sester, Martina, Abu-Omar, Amina, Becker, Sören L., Ziegler, Laura, Gärtner, Barbara C., Schmidt, Tina, Sester, Urban, Urschel, Rebecca, Mihm, Janine   +14 more
core   +3 more sources

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study

Human Vaccines & Immunotherapeutics, 2023
The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses,
Kriangkrai Tawinprai, Pawornrath Jungsomsri, Onnicha Pinijnai, Fahsiri Tavonvunchai, Anchisa Lievjaroen, Paphada Suwannaroj, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Gaidganok Sornsamdang, Teerapat Ungtrakul   +9 more
doaj   +1 more source

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination [PDF]

, 2022
We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples
Chiara Orlandi, Magnani, Mauro, Marcello Ceccarelli, Eugenio Carlotti, Ceccarelli, Marcello, Daniela Vandini, Carlotti, Eugenio, Orlandi, Chiara, Luca Galluzzi, Gloria Buffi, Barocci, Simone, Anna Casabianca, Galluzzi, Luca, Mauro Magnani, Rocchi, Marco Bruno Luigi, Casabianca, Anna, Aurora Diotallevi, Diotallevi, Aurora, Vandini, Daniela, Simone Barocci, Buffi, Gloria, Marco Bruno Luigi Rocchi   +21 more
core   +1 more source

Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2

, 2022
Despite effective vaccination programs, waning immunity in the vaccinated populations and the emergence of variants of concern posed a risk of breakthrough infections.
Venu Simhadri, Apoorva Munigela, Shashidhar Jaggaiahgari, Simhadri, Venu, Mitnala, Sasikala, D, Nageshwar Reddy, Sasikala Mitnala, Gujjarlapudi, Deepika, Deepika Gujjarlapudi, Jaggaiahgari, Shashidhar, Nageshwar Reddy D, Munigela, Apoorva   +11 more
core   +1 more source

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial

Frontiers in Immunology, 2023
Background/PurposeOptimizing vaccine efficacy is of particular concern in patients undergoing hematopoietic stem cell transplantation (HSCT), which mainly have an inadequate immune response to primary SARS-CoV-2 vaccination.
Leyla Sharifi Aliabadi, Manoochehr Karami, Manoochehr Karami, Maryam Barkhordar, Seyed Saeed Hashemi Nazari, Amir Kavousi, Mohammad Ahmadvand, Mohammad Vaezi, Mohammad Vaezi   +8 more
doaj   +1 more source

Choosing between Homologous or Heterologous COVID-19 Vaccination Regimens: A Cross-Sectional Study among the General Population in Italy [PDF]

, 2022
A shortage of COVID-19 vaccines and reports of side-effects led several countries to recommend a heterologous regimen for second vaccine doses. This study aimed to describe the reasons behind individuals’ choices of a homologous or a heterologous ...
Valerio Dimonte, Elena Casabona, Marco Clari, Albanesi, B., Rosanna Irene Comoretto, Alessio Conti, Godono, A., Dimonte, V., Clari, M., Alessandro Godono, Mansour, I., Casabona, E., Comoretto, R. I., Beatrice Albanesi, Ihab Mansour, Ciocan, C., Catalina Ciocan, Conti, A.   +17 more
core   +1 more source

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review

Infectious Diseases of Poverty, 2022
Background Heterologous prime-boost with ChAdOx1 nCoV-19 vector vaccine (ChAd) and a messenger RNA vaccine (BNT or mRNA-1273) has been widely facilitating mass coronavirus disease 2019 (COVID-19) immunisation.
Jingjing Lv, Hui Wu, Junjie Xu, Jiaye Liu   +3 more
doaj   +1 more source

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study

International Journal of Infectious Diseases, 2023
Objectives: Regarding reactogenicity and immunogenicity, heterologous COVID-19 vaccination regimens are considered as an alternative to conventional immunization schemes.
Niko Kohmer, Shivana Stein, Barbara Schenk, Katharina Grikscheit, Melinda Metzler, Holger F. Rabenau, Marek Widera, Eva Herrmann, Sabine Wicker, Sandra Ciesek   +9 more
doaj   +1 more source